Printer Friendly

JAPANESE MOHW ACCEPTS FOR REVIEW SUMMIT'S COMMERCIAL MARKETING APPLICATION

 WALTHAM, Mass., July 6 /PRNewswire/ -- Summit Technology, Inc. ("Summit" or the "Company") (NASDAQ: BEAM) today announced that it has completed human clinical trials of its excimer laser system in Japan and that the Japanese Ministry of Health and Welfare has accepted for review Summit's application to commercially sell its excimer laser systems in Japan for Photorefractive Keratectomy (PRK) and Phototherapeutic Keratectomy (PTK).
 Summit has been conducting human clinical trials of its excimer laser systems in Japan since 1989. To the best of the company's knowledge, no other company has as yet commenced human clinical trials with an excimer laser system in Japan.
 Summit Technology, Inc. has established a leadership position in designing, manufacturing and marketing ophthalmic refractive laser systems where applications have been developed for the treatment for common vision disorders such as nearsightedness, farsightedness, astigmatism, glaucoma and certain corneal irregularities due to disease or injury.
 -0- 7/6/93
 /CONTACT: Paula Rainville, investor relations, of Summit Technology, Inc., 617-890-1234/
 (BEAM)


CO: Summit Technology, Inc. ST: Massachusetts IN: MTC SU:

CM -- NE002 -- 8479 07/06/93 08:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1993
Words:179
Previous Article:DIGIBOARD ANNOUNCES DIGIVAR PROGRAM FOR RESELLERS; PROGRAM DELIVERS GREATER SUPPORT, SALES AND PROFITS TO DIGIBOARD RESELLERS
Next Article:CWE, INC. COMPLETES MERGER WITH COMPUTER SYSTEMS, INC.
Topics:


Related Articles
FDA ACCEPTS SUMMIT'S APPLICATION FOR APPROVAL TO COMMERCIALLY MARKET EXCIMER LASER SYSTEM FOR THERAPEUTIC APPLICATIONS
FDA ACCEPTS SUMMIT'S APPLICATION TO COMMERCIALLY MARKET EXCIMER LASER SYSTEMS FOR TREATMENT OF MYOPIA
FDA ACCEPTS SUMMIT'S APPLICATION TO COMMERCIALLY MARKET EXCIMER LASER SYSTEMS FOR TREATMENT OF MYOPIA
SUMMIT RESPONDS TO REPORT
SUMMIT RECEIVES FDA APPROVAL TO SELL EXCIMER LASER SYSTEM FOR PTK
SUMMIT SYSTEMS AND NIPPON STEEL CORPORATION TEAM TO OFFER DERIVATIVE TRADING AND GLOBAL RISK MANAGEMENT SOLUTIONS IN JAPAN
SciClone Announces that Schering-Plough K.K. Has Advanced the Japanese Hepatitis C Program for ZADAXIN(R) Thymosin Alpha 1
Wesley Jessen FreshLook Disposable Lenses Approved for Marketing in Japan
New Acta Fuel Cell Technology Wins Summit Medi-Chem Contract.
Kyodo economic news summary.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters